Raymond James & Associates Eli Lilly & CO Transaction History

Raymond James & Associates

  • $146 Billion
  • Q1 2024

A detailed history of Raymond James & Associates transactions in Eli Lilly & CO stock. As of the latest transaction made, Raymond James & Associates holds 935,755 shares of LLY stock, worth $846 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
935,755
Previous 866,502 7.99%
Holding current value
$846 Million
Previous $505 Million 44.13%
% of portfolio
0.5%
Previous 0.38%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024
BUY
$592.2 - $792.28 $41 Million - $54.9 Million
69,253 Added 7.99%
935,755 $728 Million
Q4 2023

Jan 16, 2024
BUY
$525.19 - $619.13 $36.3 Million - $42.8 Million
69,101 Added 8.67%
866,502 $505 Million
Q3 2023

Oct 24, 2023
SELL
$434.7 - $599.3 $9.66 Million - $13.3 Million
-22,232 Reduced 2.71%
797,401 $428 Million
Q2 2023

Jul 25, 2023
BUY
$350.74 - $468.98 $22.9 Million - $30.6 Million
65,262 Added 8.65%
819,633 $384 Million
Q1 2023

Apr 14, 2023
BUY
$310.63 - $364.82 $20.5 Million - $24.1 Million
66,003 Added 9.59%
754,371 $259 Million
Q4 2022

Feb 08, 2023
BUY
$321.55 - $374.67 $10.7 Million - $12.5 Million
33,406 Added 5.1%
688,368 $252 Million
Q3 2022

Oct 25, 2022
SELL
$296.48 - $337.87 $6.31 Million - $7.19 Million
-21,271 Reduced 3.15%
654,962 $212 Million
Q2 2022

Aug 12, 2022
SELL
$278.73 - $327.27 $6.77 Million - $7.95 Million
-24,283 Reduced 3.47%
676,233 $219 Million
Q1 2022

May 11, 2022
BUY
$234.69 - $291.66 $3.76 Million - $4.67 Million
16,021 Added 2.34%
700,516 $201 Million
Q4 2021

Feb 08, 2022
BUY
$224.85 - $279.04 $9.61 Million - $11.9 Million
42,734 Added 6.66%
684,495 $189 Million
Q3 2021

Nov 02, 2021
SELL
$221.6 - $272.71 $24.1 Million - $29.6 Million
-108,538 Reduced 14.47%
641,761 $148 Million
Q2 2021

Aug 11, 2021
BUY
$180.55 - $233.54 $13.6 Million - $17.6 Million
75,389 Added 11.17%
750,299 $172 Million
Q1 2021

May 14, 2021
BUY
$164.32 - $212.72 $2.1 Million - $2.72 Million
12,770 Added 1.93%
674,910 $126 Million
Q4 2020

Feb 12, 2021
SELL
$130.46 - $172.63 $6.29 Million - $8.33 Million
-48,230 Reduced 6.79%
662,140 $112 Million
Q3 2020

Nov 04, 2020
SELL
$146.22 - $169.13 $6.09 Million - $7.04 Million
-41,652 Reduced 5.54%
710,370 $105 Million
Q2 2020

Jul 28, 2020
SELL
$136.42 - $164.18 $5.4 Million - $6.5 Million
-39,569 Reduced 5.0%
752,022 $123 Million
Q1 2020

Apr 21, 2020
BUY
$119.05 - $147.35 $12.4 Million - $15.4 Million
104,467 Added 15.2%
791,591 $110 Million
Q4 2019

Feb 12, 2020
BUY
$106.92 - $132.43 $784,578 - $971,771
7,338 Added 1.08%
687,124 $90.3 Million
Q3 2019

Nov 07, 2019
BUY
$106.79 - $116.16 $24.5 Million - $26.6 Million
229,421 Added 50.94%
679,786 $76 Million
Q2 2019

Aug 06, 2019
SELL
$110.79 - $129.32 $7.2 Million - $8.4 Million
-64,977 Reduced 12.61%
450,365 $49.9 Million
Q1 2019

May 06, 2019
SELL
$111.31 - $131.02 $651,386 - $766,729
-5,852 Reduced 1.12%
515,342 $66.9 Million
Q4 2018

Feb 11, 2019
BUY
$105.9 - $118.64 $7.31 Million - $8.19 Million
68,996 Added 15.26%
521,194 $60.3 Million
Q3 2018

Nov 14, 2018
BUY
$85.86 - $107.31 $1.48 Million - $1.85 Million
17,283 Added 3.97%
452,198 $48.5 Million
Q2 2018

Aug 14, 2018
BUY
$75.7 - $86.88 $3.9 Million - $4.47 Million
51,504 Added 13.43%
434,915 $37.1 Million
Q1 2018

May 14, 2018
SELL
$74.21 - $87.6 $681,247 - $804,168
-9,180 Reduced 2.34%
383,411 $29.7 Million
Q4 2017

Feb 14, 2018
BUY
$81.94 - $87.89 $2.25 Million - $2.41 Million
27,463 Added 7.52%
392,591 $33.2 Million
Q3 2017

Nov 13, 2017
BUY
$77.07 - $85.54 $747,656 - $829,823
9,701 Added 2.73%
365,128 $31.2 Million
Q2 2017

Aug 14, 2017
BUY
N/A
355,427
355,427 $29.3 Million

Others Institutions Holding LLY

# of Institutions
3,718
Shares Held
738M
Call Options Held
7.09M
Put Options Held
7.24M
View Full List

About ELI LILLY & Co

LLY Quotes by TradingView
  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $860B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email